{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:20:27Z","timestamp":1787656827935,"version":"build-2736575974"},"reference-count":81,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA168762"],"award-info":[{"award-number":["CA168762"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA186781"],"award-info":[{"award-number":["CA186781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Bispecific antibodies have reshaped the therapeutic landscape for relapsed\/refractory multiple myeloma (RRMM), complementing proteasome inhibitors, IMiDs, and anti\u2010CD38 antibodies and competing with BCMA\u2010directed CAR\u2010T cells. In this review, we discuss the structure, mechanisms of action, and clinical data for currently approved and emerging T\u2010cell redirecting antibodies and discuss practical questions around sequencing with CAR\u2010T therapy, toxicity mitigation, and resistance. Bispecific T\u2010cell engagers have shown high response rates in early relapse, as well as multidrug\u2010refractory disease and post\u2010CAR\u2010T relapse, but are limited by continuous dosing, infections, hypogammaglobulinemia, cytopenias, cytokine release syndrome (CRS), and neurologic toxicity. We review emerging concepts in resistance like T\u2010cell exhaustion, antigen loss, soluble BCMA, and extramedullary disease and discuss strategies to enhance efficacy, including combinations with anti\u2010CD38 antibodies and IMiDs. Bispecific antibodies have become indispensable in relapsed myeloma, and for patients who are ineligible for or relapse after CAR\u2010T therapy. With multiple clinical trials and new molecules in development, rational sequencing and combination approaches will determine how far their promise translates into durable disease control.<\/jats:p>","DOI":"10.1111\/ejh.70301","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:36:07Z","timestamp":1787654167000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific Antibodies and T\u2010Cell Engagers in Multiple Myeloma"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-2057","authenticated-orcid":false,"given":"Mahin","family":"Bhatt","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"1","key":"e_1_2_19_2_1","first-page":"17","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel R. L.","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"e_1_2_19_3_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","article-title":"BCMA\u2010Directed Therapy, New Treatments in the Myeloma Toolbox, and How to Use Them","volume":"65","author":"Rees M. J.","year":"2024","journal-title":"Leukemia & Lymphoma"},{"issue":"7","key":"e_1_2_19_4_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical Course of Patients With Relapsed Multiple Myeloma","volume":"79","author":"Kumar S. K.","year":"2004","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"e_1_2_19_5_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple Myeloma: Patient Outcomes in Real\u2010World Practice","volume":"175","author":"Yong K.","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"5","key":"e_1_2_19_6_1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A Prospective, Non\u2010Interventional, Multinational Study of Real\u2010Life Current Standards of Care in Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"36","author":"Mateos M. V.","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"e_1_2_19_7_1","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of Patients With Multiple Myeloma Refractory to CD38\u2010Targeted Monoclonal Antibody Therapy","volume":"33","author":"Gandhi U. H.","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"e_1_2_19_8_1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study","volume":"31","author":"Kumar S. K.","year":"2017","journal-title":"Leukemia"},{"key":"e_1_2_19_9_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific Antibodies in Multiple Myeloma Treatment: A Journey in Progress","volume":"12","author":"Cho S. F.","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"8","key":"e_1_2_19_10_1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A Novel BCMA\/CD3 Bispecific T\u2010Cell Engager for the Treatment of Multiple Myeloma Induces Selective Lysis In\u00a0Vitro and In\u00a0Vivo","volume":"31","author":"Hipp S.","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_19_11_1","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional Hyper\u2010Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma","volume":"140","author":"Neri P.","year":"2022","journal-title":"Blood"},{"issue":"11","key":"e_1_2_19_12_1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 Overexpression in Multiple Myeloma Bone Marrow as a Sign of Accumulation of CD4(+) T Regulatory Cells","volume":"63","author":"Braga W. M.","year":"2014","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"5934","key":"e_1_2_19_13_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/305537a0","article-title":"Hybrid Hybridomas and Their Use in Immunohistochemistry","volume":"305","author":"Milstein C.","year":"1983","journal-title":"Nature"},{"key":"e_1_2_19_14_1","first-page":"71","article-title":"Chemical Production of Bispecific Antibodies","volume":"283","author":"Graziano R. F.","year":"2004","journal-title":"Methods in Molecular Biology"},{"issue":"5","key":"e_1_2_19_15_1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.drudis.2015.02.013","article-title":"The Coming of Age of Engineered Multivalent Antibodies","volume":"20","author":"Nu\u00f1ez\u2010Prado N.","year":"2015","journal-title":"Drug Discovery Today"},{"issue":"13","key":"e_1_2_19_16_1","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient Generation of Stable Bispecific IgG1 by Controlled Fab\u2010Arm Exchange","volume":"110","author":"Labrijn A. F.","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"17","key":"e_1_2_19_17_1","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2011-02-337691","article-title":"DARTs Take Aim at BiTEs","volume":"117","author":"Rader C.","year":"2011","journal-title":"Blood"},{"issue":"9","key":"e_1_2_19_18_1","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114291","article-title":"The State of the Art of Bispecific Antibodies for Treating Human Malignancies","volume":"13","author":"Wang S.","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"e_1_2_19_19_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.626616","article-title":"Bispecific Antibodies: From Research to Clinical Application","volume":"12","author":"Ma J.","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"e_1_2_19_20_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau P.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_19_21_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real\u2010World Analysis of Teclistamab in 123 RRMM Patients From Germany","volume":"38","author":"Riedhammer C.","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"e_1_2_19_22_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2603870","article-title":"Teclistamab in Multiple Myeloma With One to Three Previous Lines of Therapy","volume":"395","author":"Touzeau C.","year":"2026","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_19_23_1","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM\u20103 Trial Results","volume":"29","author":"Lesokhin A. M.","year":"2023","journal-title":"Nature Medicine"},{"key":"e_1_2_19_24_1","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1016\/j.htct.2023.09.764","article-title":"Elranatamab, a B\u2010Cell Maturation Antigen\u2010Cd3 Bispecific Antibody, for Patients With Relapsed\/Refractory Multiple Myeloma: Extended Follow Up and Biweekly Administration From the Magnetismm\u20103 Study","volume":"45","author":"Mohty M.","year":"2023","journal-title":"Hematology, Transfusion and Cell Therapy"},{"key":"e_1_2_19_25_1","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/j.htct.2023.09.765","article-title":"Efficacy and Safety of ELRANATAMAB in Patients With Relapsed or Refractory Multiple Myeloma and Prior B\u2010Cell Maturation Antigen\u2013Directed Therapies: A Pooled Analysis From MAGNETISMM Studies","volume":"45","author":"Nooka A.","year":"2023","journal-title":"Hematology, Transfusion and Cell Therapy"},{"issue":"24","key":"e_1_2_19_26_1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T\u2010Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari A.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"e_1_2_19_27_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146868","article-title":"Updated Phase 1 Results From MonumenTAL\u20101: First\u2010In\u2010Human Study of Talquetamab, a G Protein\u2010Coupled Receptor Family C Group 5 Member D \u00d7 CD3 Bispecific Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Krishnan A. Y.","year":"2021","journal-title":"Blood"},{"key":"e_1_2_19_28_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal Phase 2 MonumenTAL\u20101 Results of Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"41","author":"Carolina D. Schinke C. T.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_19_29_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients With Heavily Pre\u2010Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results From an Ongoing Phase I Study","volume":"138","author":"Trudel S.","year":"2021","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_30_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-199542","article-title":"Cevostamab in Patients With Heavily Pretreated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results From an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies","volume":"144","author":"Richter J.","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_31_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182388","article-title":"Updated Safety and Efficacy Results of Abbv\u2010383, a BCMA \u00d7 CD3 Bispecific T\u2010Cell Redirecting Antibody, in a First\u2010In\u2010Human Phase 1 Study in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Vij R.","year":"2023","journal-title":"Blood"},{"issue":"4","key":"e_1_2_19_32_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/abt\/tbab022","article-title":"Development of a Reporter Gene Method to Measure the Bioactivity of Anti\u2010CD38 \u00d7 CD3 Bispecific Antibody","volume":"4","author":"Xiong H.","year":"2021","journal-title":"Antibody Therapeutics"},{"issue":"2","key":"e_1_2_19_33_1","article-title":"1528\u2009A Phase I Study of a Novel BCMA\u00d7CD3 Bispecific Antibody EMB06 in Relapsed or Refractory Multiple Myeloma","volume":"11","author":"Tan P.","year":"2023","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"e_1_2_19_34_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-193738","article-title":"A Phase I Study of a Novel BCMA\u00d7CD3 Bispecific Antibody Emb\u201006 in Relapsed or Refractory Multiple Myeloma","volume":"144","author":"Tan P.","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_35_1","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.1182\/blood-2022-158146","article-title":"Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T\u2010Cell Engaging Bispecific Antibody, Is Highly Active in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM): Biomarker Results From a Phase I Study","volume":"140","author":"Dekhtiarenko I.","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_36_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T\u2010Cell Engaging Bispecific Antibody, Is Highly Active in Patients (Pts) With Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results From a Phase I Dose\u2010Escalation Study","volume":"140","author":"Carlo\u2010Stella C.","year":"2022","journal-title":"Blood"},{"issue":"7","key":"e_1_2_19_37_1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1\u2010NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells Against Multiple Myeloma","volume":"6","author":"Chan W. K.","year":"2018","journal-title":"Cancer Immunology Research"},{"issue":"13","key":"e_1_2_19_38_1","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-5671","article-title":"Abstract 5671: AFM26\u2014A Novel CD16A\u2010Directed Bispecific TandAb Targeting BCMA for Multiple Myeloma","volume":"77","author":"Gantke T.","year":"2017","journal-title":"Cancer Research"},{"issue":"1","key":"e_1_2_19_39_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-2354","article-title":"Ex Vivo Expanded Adaptive NK Cells in Combination With a Bispecific NK Cell Engager Targeting BCMA for Synergistic Control of Multiple Myeloma","volume":"146","author":"Boxaspen T.","year":"2025","journal-title":"Blood"},{"issue":"8","key":"e_1_2_19_40_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab Plus Daratumumab in Relapsed or Refractory Multiple Myeloma","volume":"394","author":"Costa L. J.","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"e_1_2_19_41_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2604657","article-title":"Talquetamab\u2013Daratumumab in Relapsed or Refractory Myeloma","volume":"395","author":"Mina R.","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"e_1_2_19_42_1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2025029773","article-title":"Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D Bispecific Antibody, as a Bridge to BCMA CAR\u2010T Therapy","volume":"146","author":"Dhakal B.","year":"2025","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_43_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual Targeting of Extramedullary Myeloma With Talquetamab and Teclistamab","volume":"394","author":"Kumar S.","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_19_44_1","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group Immunotherapy Committee Consensus Guidelines and Recommendations for Optimal Use of T\u2010Cell\u2010Engaging Bispecific Antibodies in Multiple Myeloma","volume":"25","author":"Rodriguez\u2010Otero P.","year":"2024","journal-title":"Lancet Oncology"},{"key":"e_1_2_19_45_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-190517","article-title":"Immune and Genome Profiling of Myeloma Patients Treated With Sequential Immunotherapies Reveal Differential Non\u2010Overlapping Mechanisms of Resistance","volume":"142","author":"Lee H.","year":"2023","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_46_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-188080","article-title":"The Impact of Soluble BCMA and BCMA Gain on Anti\u2010BCMA Immunotherapies in Multiple Myeloma","volume":"142","author":"Lee H.","year":"2023","journal-title":"Blood"},{"issue":"13","key":"e_1_2_19_47_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA\u2010 or GPRC5D\u2010Targeting Bispecific Antibodies in Multiple Myeloma: Efficacy, Safety, and Resistance Mechanisms","volume":"143","author":"Lee H.","year":"2024","journal-title":"Blood"},{"issue":"8","key":"e_1_2_19_48_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune\u2010Based Therapies in the Management of Multiple Myeloma","volume":"10","author":"Zanwar S.","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"7","key":"e_1_2_19_49_1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and Outcomes of Patients With Multiple Myeloma Receiving Salvage Therapy After BCMA\u2010Directed CAR T Therapy","volume":"141","author":"Van Oekelen O.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_19_50_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","article-title":"Efficacy and Safety of Teclistamab (Tec), a B\u2010Cell Maturation Antigen (BCMA) \u00d7 CD3 Bispecific Antibody, in Patients (Pts) With Relapsed\/Refractory Multiple Myeloma (RRMM) After Exposure to Other BCMA\u2010Targeted Agents","volume":"40","author":"Touzeau C.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_19_51_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real\u2010World Experience of Patients With Multiple Myeloma Receiving Ide\u2010Cel After a Prior BCMA\u2010Targeted Therapy","volume":"13","author":"Ferreri C. J.","year":"2023","journal-title":"Blood Cancer Journal"},{"issue":"11","key":"e_1_2_19_52_1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real\u2010World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen D. K.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"e_1_2_19_53_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi N. C.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"e_1_2_19_54_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and Safety of Cilta\u2010Cel in Patients With Progressive Multiple Myeloma After Exposure to Other BCMA\u2010Targeting Agents","volume":"141","author":"Cohen A. D.","year":"2023","journal-title":"Blood"},{"issue":"6","key":"e_1_2_19_55_1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T\u2010Cell Redirection Therapies Leads to Deep and Durable Responses in Patients With Relapsed\/Refractory Myeloma","volume":"7","author":"Mouhieddine T. H.","year":"2023","journal-title":"Blood Advances"},{"key":"e_1_2_19_56_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206715","article-title":"\u201cWaitlist Mortality\u201d Is High for Myeloma Patients With Limited Access to BCMA Therapy","volume":"13","author":"Ahmed N.","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"10","key":"e_1_2_19_57_1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T\u2010Cell Exhaustion Induced by Continuous Bispecific Molecule Exposure Is Ameliorated by Treatment\u2010Free Intervals","volume":"140","author":"Philipp N.","year":"2022","journal-title":"Blood"},{"issue":"16","key":"e_1_2_19_58_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (Tal) + Daratumumab (Dara) in Patients (Pts) With Relapsed\/Refractory Multiple Myeloma (RRMM): Updated TRIMM\u20102 Results","volume":"41","author":"Dholaria B. R.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_19_59_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume-title":"First Results From the RedirecTT\u20101 Study With Teclistamab (Tec)+ Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients (Pts) With Relapsed\/Refractory Multiple Myeloma (RRMM)","author":"Cohen Y. C.","year":"2023"},{"issue":"1","key":"e_1_2_19_60_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in Combination With Subcutaneous Daratumumab and Lenalidomide in Patients With Multiple Myeloma: Results From One Cohort of MajesTEC\u20102, a Phase1b, Multicohort Study","volume":"140","author":"Searle E.","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_61_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in Patients With Relapsed\/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results From the Phase 1b MonumenTAL\u20102 Study","volume":"142","author":"Matous J.","year":"2023","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_62_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12885-022-10458-x","article-title":"Patient Perspectives on Considerations, Tradeoffs, and Experiences With Multiple Myeloma Treatment Selection: A Qualitative Descriptive Study","volume":"23","author":"Dombeck C.","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"e_1_2_19_63_1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health\u2010Related Quality of Life With Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"6","author":"Delforge M.","year":"2022","journal-title":"Blood Advances"},{"issue":"13","key":"e_1_2_19_64_1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed Overview of Incidence and Management of Cytokine Release Syndrome Observed With Teclistamab in the MajesTEC\u20101 Study of Patients With Relapsed\/Refractory Multiple Myeloma","volume":"129","author":"Martin T. G.","year":"2023","journal-title":"Cancer"},{"issue":"13","key":"e_1_2_19_65_1","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of Infections Associated With the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis","volume":"7","author":"Mazahreh F.","year":"2023","journal-title":"Blood Advances"},{"issue":"6","key":"e_1_2_19_66_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated With Ten\u2010Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated With Anti\u2010BCMA Bispecific Antibodies","volume":"4","author":"Lancman G.","year":"2023","journal-title":"Blood Cancer Discovery"},{"issue":"6","key":"e_1_2_19_67_1","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and Management of Adverse Events During Treatment With Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network","volume":"24","author":"Ludwig H.","year":"2023","journal-title":"Lancet Oncology"},{"issue":"1","key":"e_1_2_19_68_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B\u2010Cell Maturation Antigen (BCMA) \u00d7 CD3 Bispecific Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM): Correlative Analyses From MajesTEC\u20101","volume":"140","author":"Cortes\u2010Selva D.","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_19_69_1","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3\u2010Secretase Directly Sheds the Survival Receptor BCMA From Plasma Cells","volume":"6","author":"Laurent S. A.","year":"2015","journal-title":"Nature Communications"},{"key":"e_1_2_19_70_1","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2023-190341","article-title":"Soluble B\u2010Cell Maturation Antigen as a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation From Elranatamab (ELRA) Magnetismm Studies","volume":"142","author":"Elmeliegy M.","year":"2023","journal-title":"Blood"},{"issue":"3","key":"e_1_2_19_71_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13666","article-title":"Baseline Serum B\u2010Cell Maturation Antigen Levels Predict Time to Disease Progression for Patients With Smoldering Multiple Myeloma","volume":"107","author":"Bujarski S.","year":"2021","journal-title":"European Journal of Haematology"},{"issue":"4","key":"e_1_2_19_72_1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of Teclistamab and Talquetamab on Soluble BCMA Levels in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"7","author":"Girgis S.","year":"2023","journal-title":"Blood Advances"},{"issue":"13","key":"e_1_2_19_73_1","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B\u2010Cell Maturation Antigen Mediates Tumor\u2010Induced Immune Deficiency in Multiple Myeloma","volume":"22","author":"Sanchez E.","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"e_1_2_19_74_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T\u2010Cell Expansion, and Skews T\u2010Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik J.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_19_75_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.HS9.0000843644.02496.66","article-title":"S188: TECLISTAMAB in Combination With DARATUMUMAB, A Novel, Immunotherapy\u2010Based Approach for the Treatment of Relapsed\/Refractory Multiple Myeloma: Updated Phase 1B Results","volume":"6","author":"Rodriguez Otero P.","year":"2022","journal-title":"HemaSphere"},{"issue":"8","key":"e_1_2_19_76_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3\u2010Secretase Inhibitors Augment Efficacy of BCMA\u2010Targeting Bispecific Antibodies Against Multiple Myeloma Cells Without Impairing T\u2010Cell Activation and Differentiation","volume":"12","author":"Chen H.","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"8","key":"e_1_2_19_77_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD\u2010L1 Blockade","volume":"17","author":"Hallett W. H. D.","year":"2011","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"e_1_2_19_78_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T\u2010Cell Exhaustion in Multiple Myeloma Relapse After Autotransplant: Optimal Timing of Immunotherapy","volume":"4","author":"Chung D. J.","year":"2016","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"e_1_2_19_79_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune Checkpoint Inhibitors for Multiple Myeloma Immunotherapy","volume":"12","author":"Liu Z.","year":"2023","journal-title":"Experimental Hematology & Oncology"},{"issue":"20","key":"e_1_2_19_80_1","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade\u2010Induced Immune Response in Multiple Myeloma","volume":"21","author":"G\u00f6rg\u00fcn G.","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"e_1_2_19_81_1","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab Combined With Lenalidomide and Low\u2010Dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE\u2010023 Study","volume":"186","author":"Mateos M. V.","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"3","key":"e_1_2_19_82_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD\u20101\/PD\u2010L1 Axis in Multiple Myeloma: A Dream or a Reality?","volume":"129","author":"Rosenblatt J.","year":"2017","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:36:18Z","timestamp":1787654178000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":81,"alternative-id":["10.1111\/ejh.70301"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70301","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"2025-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70301"}}